A review of Venezuela’s current crisis has given cause for concern, highlighting the increased rate of re-emergence and spread of vector-borne diseases such as malaria, Chagas disease, dengue and Zika virus.
Researchers from the Wistar Institute have engineered a synthetic DNA vaccine able to provide potent immunity against the emerging Mayaro virus in mice models.
Take a look at this month’s industry headlines including an FDA approval for a vaccine protecting against six diseases, positive clinical trial results for bacteraemia and dengue vaccines and new funding for CRSIPR-based antimicrobials.
Madariaga virus has been identified as the cause of acute febrile illness in eight children in Haiti between 2015 and 2016 – the first time it has been discovered in the country.
An mRNA-based vaccine has been demonstrated to protect against Powassan virus in mice, in addition to also conferring protection against the more distantly related Langat virus.
Ebola case numbers reach 426 in the current outbreak in the Democratic Republic of Congo, making this the second largest ever seen for the virus.
A new trial has begun in the Democratic Republic of Congo, aiming to collect robust data on the safety and efficacy of investigational Ebola therapeutics.
Take a look behind the scenes of a recent Future Virology paper as we ask author Prof. Mohamed El Zowalaty about the challenges facing the field of arboviruses, from climate change to urbanization, both in South Africa and across the world.
The US FDA has granted priority review for Sanofi Pasteur’s dengue vaccine, Dengvaxia®, despite its controversial past.
A team from the Okinawa Institute of Science and Technology Graduate University has used cryo-EM to model the nucleocapsid protein of Ebola virus, potentially uncovering novel drug targets.
